Skip to content
DataLookout
Menu

Changes this week

Changes detected in the 7 days to Nov 20, 2026

  1. Notable: Simple-Prep Controlled Embolic Results posted: Nov 19, 2026 Fluidx Medical Technology, Inc.Not applicable NCT06453642
  2. Notable: Nutrition and Swelling Primary endpoint(s) modified University of California, San FranciscoPhase 2 NCT07899762
  3. Notable: SIRIUS - Initial Combination Therapy With an Endothelin Receptor Antagonist, a Phosphodiesterase-5 Inhibitor and Sotatercept · Newly Diagnosed Pulmonary Arterial Hypertension Primary endpoint(s) modified Philipps University MarburgPhase 2 NCT07266519
  4. Notable: Propranolol Hydrochloride in Combination With Sintilimab and Platinum-based Chemotherapy · Advanced Non-small Cell Lung Cancer Primary completion pushed from Aug 31, 2025 to Oct 31, 2028 Second Xiangya Hospital of Central South UniversityPhase 1/2 NCT05979818
  5. Notable: Vinpocetine in Healthy Volunteers Primary and study completion pushed from Jun 1, 2026 to Dec 31, 2026 Stanford UniversityPhase 1 NCT06635746
  6. Notable: Talazoparib + Tazemetostat for mCRPC Results posted: Nov 19, 2026 Dana-Farber Cancer InstitutePhase 1 NCT04846478
  7. Notable: Building Healthy Food Environment in Schools: Evaluating Co-created Interventions in Low Resource Settings. #BetterNutrition4Adolescent Enrollment increased: 2600 → 4464 participants Norwegian University of Science and TechnologyNot applicable NCT07332676
  8. Notable: Automated, Assistive, Non-Contact Sleep Quality Monitor for Older Adults Recruitment opened Indiana UniversityNot applicable NCT06045988
  9. Notable: BFR and Neuromuscular Training in Knee Osteoarthritis (KOA) Primary endpoint(s) modified University of LahoreNot applicable NCT07942883
  10. Notable: Screen Time Exposure and Behavioral Outcomes Primary endpoint(s) modified Sohag UniversityNot specified NCT07941596
  11. Notable: Cost-Effectiveness of the Healthy Beat Acupunch Regimen in Community-Dwelling Older Adults Primary endpoint(s) modified Mahidol UniversityNot applicable NCT07868575
  12. Notable: Perianchor Cyst Formation, Tendon Healing, and Clinical Outcomes Following Arthroscopic Rotator Cuff Repair Primary endpoint(s) modified Fatih Sultan Mehmet Training and Research HospitalNot specified NCT07661680
  13. Notable: Exercise Intervention to Increase Physical Activity in Young Sarcoma Survivors (Sport Ist Herzenssache) Recruitment opened Universität Duisburg-EssenNot applicable NCT07729059
  14. Notable: Empowered Relief for Caregivers Recruitment opened Stanford UniversityNot applicable NCT07636980
  15. Notable: SHOFU FX-LC RMGI Restoration Versus FUJI II RGMI · Anterior Carious Cervical Lesions Enrollment increased: 36 → 56 participants Cairo UniversityNot applicable NCT07937176
  16. Notable: Systemic Therapy Alone and With Local Ablative Treatment for Stage IV Non-Small Cell Lung Cancer Patients Primary endpoint(s) modified Swiss Cancer InstituteNot applicable NCT06114108
  17. Notable: Validation of AR Based Neuronavigation System Recruitment opened Seoul National University HospitalNot applicable NCT05776706
  18. Notable: Paclitaxel Polymeric Micelles for Injection · Metastatic Breast Cancer Primary completion pushed from Dec 2025 to Dec 31, 2027 Shanghai Yizhong Pharmaceutical Co., Ltd.Phase 3 NCT06143553
  19. Notable: Pacritinib · VEXAS Syndrome (PAXIS) Primary completion pushed from Dec 30, 2026 to Oct 30, 2028 Swedish Orphan BiovitrumPhase 2 NCT06782373
  20. Notable: REC-1245 · Unresectable, Locally Advanced, or Metastatic Cancer Primary and study completion pushed from Oct 30, 2028 to Jul 2029 Recursion Pharmaceuticals Inc.Phase 1/2 NCT06678659
  21. Notable: SNH-119014 · Non-transfusion-dependent Thalassemia (NTDT) Primary completion pushed from Mar 29, 2027 to Sep 30, 2027 ScinnoHub Pharmaceutical Co., Ltd.Phase 2 NCT07579949
  22. Notable: Abemaciclib and Elacestrant · Brain Metastasis Due to ER+/HER-2- Breast Cancer Primary completion pushed from Dec 2026 to Aug 2027 Stemline Therapeutics, Inc.Phase 1/2 NCT05386108
  23. Notable: Use of Drug Product Reamberin® for Pathogenetic Therapy of Viral Enteric Infection in Children Aged 1-6 Years Old Primary completion pushed from Jun 2026 to Jun 2027 POLYSAN Scientific & Technological Pharmaceutical CompanyNot specified NCT07066540
  24. Notable: (EFS) Evaluating Percutaneous Repair of the Atrial Septum With a Novel PFO Occluder: The PROTEA-PFO Study Primary completion pushed from Aug 2026 to Aug 2027 Recross Cardio, Inc.Not applicable NCT07172464
  25. Notable: Efficiency of Cytoflavin, · Ischemic Stroke Not Receiving Reperfusion Therapy Primary completion pushed from Sep 30, 2025 to Jun 1, 2027 POLYSAN Scientific & Technological Pharmaceutical CompanyNot specified NCT06514976